Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

Masanobu Tsuda, Yuki Moritoki, Zhe Xiong Lian, Weici Zhang, Katsunori Yoshida, Kanji Wakabayashi, Guo Xiang Yang, Toshio Nakatani, John Vierling, Keith Lindor, M. Eric Gershwin, Christopher Bowlus

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

The aim of this study was to determine the safety and potential efficacy of B-cell depletion with the anti-CD20 monoclonal antibody rituximab in patients with primary biliary cirrhosis (PBC) and an incomplete response to ursodeoxycholic acid (UDCA). This open-label study enrolled six patients with PBC and incomplete responses to UDCA to be treated with 2 doses of 1000 mg rituximab separated by 2 weeks and followed for 52 weeks. The primary endpoints were safety and changes in B-cell function. Two patients received only 1 dose of rituximab, one due to activation of latent varicella and the other due to a viral upper respiratory infection. Serum levels of total IgG, IgM, and IgA as well as anti-mitochondrial autoantibodies (AMAs) IgA and IgM decreased significantly from baseline by 16 weeks and returned to baseline levels by 36 weeks. Stimulation of B cells with CpG produced significantly less IgM at 52 weeks after treatment compared with B cells at baseline. In addition, transient decreases in memory B-cell and T-cell frequencies and an increase in CD25 high CD4 + T cells were observed after treatment. These changes were associated with significant increases in mRNA levels of FoxP3 and transforming growth factor-β (TGF-β) and a decrease in tumor necrosis factor-α (TNF-α) in CD4 + T cells. Notably, serum alkaline phosphatase levels were significantly reduced up to 36 weeks following rituximab treatment. Conclusion: These data suggest that depletion of B cells influences the induction, maintenance, and activation of both B and T cells and provides a potential mechanism for treatment of patients with PBC with an incomplete response to UDCA.

Original languageEnglish (US)
Pages (from-to)512-521
Number of pages10
JournalHepatology
Volume55
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Ursodeoxycholic Acid
Biliary Liver Cirrhosis
B-Lymphocytes
T-Lymphocytes
Immunoglobulin M
Immunoglobulin A
Safety
Chickenpox
Transforming Growth Factors
Therapeutics
Rituximab
Serum
Respiratory Tract Infections
Autoantibodies
Alkaline Phosphatase
Tumor Necrosis Factor-alpha
Immunoglobulin G
Monoclonal Antibodies
Maintenance
Messenger RNA

ASJC Scopus subject areas

  • Hepatology

Cite this

Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. / Tsuda, Masanobu; Moritoki, Yuki; Lian, Zhe Xiong; Zhang, Weici; Yoshida, Katsunori; Wakabayashi, Kanji; Yang, Guo Xiang; Nakatani, Toshio; Vierling, John; Lindor, Keith; Gershwin, M. Eric; Bowlus, Christopher.

In: Hepatology, Vol. 55, No. 2, 02.2012, p. 512-521.

Research output: Contribution to journalArticle

Tsuda, M, Moritoki, Y, Lian, ZX, Zhang, W, Yoshida, K, Wakabayashi, K, Yang, GX, Nakatani, T, Vierling, J, Lindor, K, Gershwin, ME & Bowlus, C 2012, 'Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid', Hepatology, vol. 55, no. 2, pp. 512-521. https://doi.org/10.1002/hep.24748
Tsuda, Masanobu ; Moritoki, Yuki ; Lian, Zhe Xiong ; Zhang, Weici ; Yoshida, Katsunori ; Wakabayashi, Kanji ; Yang, Guo Xiang ; Nakatani, Toshio ; Vierling, John ; Lindor, Keith ; Gershwin, M. Eric ; Bowlus, Christopher. / Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. In: Hepatology. 2012 ; Vol. 55, No. 2. pp. 512-521.
@article{0a8a25fed0ca468fa0fc73c8332ca569,
title = "Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid",
abstract = "The aim of this study was to determine the safety and potential efficacy of B-cell depletion with the anti-CD20 monoclonal antibody rituximab in patients with primary biliary cirrhosis (PBC) and an incomplete response to ursodeoxycholic acid (UDCA). This open-label study enrolled six patients with PBC and incomplete responses to UDCA to be treated with 2 doses of 1000 mg rituximab separated by 2 weeks and followed for 52 weeks. The primary endpoints were safety and changes in B-cell function. Two patients received only 1 dose of rituximab, one due to activation of latent varicella and the other due to a viral upper respiratory infection. Serum levels of total IgG, IgM, and IgA as well as anti-mitochondrial autoantibodies (AMAs) IgA and IgM decreased significantly from baseline by 16 weeks and returned to baseline levels by 36 weeks. Stimulation of B cells with CpG produced significantly less IgM at 52 weeks after treatment compared with B cells at baseline. In addition, transient decreases in memory B-cell and T-cell frequencies and an increase in CD25 high CD4 + T cells were observed after treatment. These changes were associated with significant increases in mRNA levels of FoxP3 and transforming growth factor-β (TGF-β) and a decrease in tumor necrosis factor-α (TNF-α) in CD4 + T cells. Notably, serum alkaline phosphatase levels were significantly reduced up to 36 weeks following rituximab treatment. Conclusion: These data suggest that depletion of B cells influences the induction, maintenance, and activation of both B and T cells and provides a potential mechanism for treatment of patients with PBC with an incomplete response to UDCA.",
author = "Masanobu Tsuda and Yuki Moritoki and Lian, {Zhe Xiong} and Weici Zhang and Katsunori Yoshida and Kanji Wakabayashi and Yang, {Guo Xiang} and Toshio Nakatani and John Vierling and Keith Lindor and Gershwin, {M. Eric} and Christopher Bowlus",
year = "2012",
month = "2",
doi = "10.1002/hep.24748",
language = "English (US)",
volume = "55",
pages = "512--521",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

AU - Tsuda, Masanobu

AU - Moritoki, Yuki

AU - Lian, Zhe Xiong

AU - Zhang, Weici

AU - Yoshida, Katsunori

AU - Wakabayashi, Kanji

AU - Yang, Guo Xiang

AU - Nakatani, Toshio

AU - Vierling, John

AU - Lindor, Keith

AU - Gershwin, M. Eric

AU - Bowlus, Christopher

PY - 2012/2

Y1 - 2012/2

N2 - The aim of this study was to determine the safety and potential efficacy of B-cell depletion with the anti-CD20 monoclonal antibody rituximab in patients with primary biliary cirrhosis (PBC) and an incomplete response to ursodeoxycholic acid (UDCA). This open-label study enrolled six patients with PBC and incomplete responses to UDCA to be treated with 2 doses of 1000 mg rituximab separated by 2 weeks and followed for 52 weeks. The primary endpoints were safety and changes in B-cell function. Two patients received only 1 dose of rituximab, one due to activation of latent varicella and the other due to a viral upper respiratory infection. Serum levels of total IgG, IgM, and IgA as well as anti-mitochondrial autoantibodies (AMAs) IgA and IgM decreased significantly from baseline by 16 weeks and returned to baseline levels by 36 weeks. Stimulation of B cells with CpG produced significantly less IgM at 52 weeks after treatment compared with B cells at baseline. In addition, transient decreases in memory B-cell and T-cell frequencies and an increase in CD25 high CD4 + T cells were observed after treatment. These changes were associated with significant increases in mRNA levels of FoxP3 and transforming growth factor-β (TGF-β) and a decrease in tumor necrosis factor-α (TNF-α) in CD4 + T cells. Notably, serum alkaline phosphatase levels were significantly reduced up to 36 weeks following rituximab treatment. Conclusion: These data suggest that depletion of B cells influences the induction, maintenance, and activation of both B and T cells and provides a potential mechanism for treatment of patients with PBC with an incomplete response to UDCA.

AB - The aim of this study was to determine the safety and potential efficacy of B-cell depletion with the anti-CD20 monoclonal antibody rituximab in patients with primary biliary cirrhosis (PBC) and an incomplete response to ursodeoxycholic acid (UDCA). This open-label study enrolled six patients with PBC and incomplete responses to UDCA to be treated with 2 doses of 1000 mg rituximab separated by 2 weeks and followed for 52 weeks. The primary endpoints were safety and changes in B-cell function. Two patients received only 1 dose of rituximab, one due to activation of latent varicella and the other due to a viral upper respiratory infection. Serum levels of total IgG, IgM, and IgA as well as anti-mitochondrial autoantibodies (AMAs) IgA and IgM decreased significantly from baseline by 16 weeks and returned to baseline levels by 36 weeks. Stimulation of B cells with CpG produced significantly less IgM at 52 weeks after treatment compared with B cells at baseline. In addition, transient decreases in memory B-cell and T-cell frequencies and an increase in CD25 high CD4 + T cells were observed after treatment. These changes were associated with significant increases in mRNA levels of FoxP3 and transforming growth factor-β (TGF-β) and a decrease in tumor necrosis factor-α (TNF-α) in CD4 + T cells. Notably, serum alkaline phosphatase levels were significantly reduced up to 36 weeks following rituximab treatment. Conclusion: These data suggest that depletion of B cells influences the induction, maintenance, and activation of both B and T cells and provides a potential mechanism for treatment of patients with PBC with an incomplete response to UDCA.

UR - http://www.scopus.com/inward/record.url?scp=84863072278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863072278&partnerID=8YFLogxK

U2 - 10.1002/hep.24748

DO - 10.1002/hep.24748

M3 - Article

VL - 55

SP - 512

EP - 521

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -